Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly...

Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial BMJ. 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012)

HYVET 1-year extension: Immediate and late benefits with indapamide SR ± perindopril in the treatment of hypertensive patients.

HYVET 1-year extensionHYVET 1-year extension11 Study protocolStudy protocol

3.1 years on active treatment

1 year on active treatment

n= 3845 patients n= 1712 patients

Placebo

Placebo

Indapamide SR± perindopril



2.1 years 1-year extension2.1 years

1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012)

vs.

HYVET HYVET 11 ResultsResults

n= 3845 patients

Placebo

Placebo


2.1 yearsStroke hazard ratio: -39% P =0.05 in favor of the indapamide SR ± perindopril group.

Heart failurehazard ratio: -64% P<0.001 in favor of the indapamide SR ± perindopril group.

All-cause mortality hazard ratio: -21% P=0.02 in favor of the indapamide SR ± perindopril group.

1. Beckett NS, Peters R, Fletcher AE, et al. N Engl J Med. 2008;358:1887-1898.

Cardiovascular events hazard ratio: -34% P<0.001 in favor of the indapamide SR ± perindopril group.

Cardiovascular mortality hazard ratio: -23% P=0.06 in favor of the indapamide SR ± perindopril group.

vs.

HYVET 1-year extensionHYVET 1-year extension11 Study protocolStudy protocol

3.1 years on active treatment

1 year on active treatment


Placebo

Placebo





2.1 years 1-year extension

vs.

No significant difference between the two arms in:- Stroke P=0.28- Heart failure P=0.28- Cardiovascular events P=0.55

HYVET 1-year extensionHYVET 1-year extension11 ResultsResults

• Indapamide SR ± perindopril provides patients with immediate protection against stroke, heart failure, and cardiovascular events

• These benefits appeared within 1 year of starting treatment

• Indapamide SR ± perindopril provides patients with immediate protection against stroke, heart failure, and cardiovascular events

• These benefits appeared within 1 year of starting treatment


Placebo

Placebo






vs.

• Indapamide SR ± perindopril provides cumulative time-dependent life-saving benefits, increased over the long term.


Total mortality hazard ratio: -52% P =0.02 in favor of the group treated for 3.1 years.

Cardiovascular mortality hazard ratio: -81% P =0.03 in favor of the group treated for3.1 years.n= 3845 patients n= 1712 patients

Placebo

Placebo







vs.





Total mortality Cardiovascular mortality

P=0.02

P=0.03

-52%

-81%

Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly...

Documents

Transcript of Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly...